Abstract:Aims: The present study investigated the effect of Escherichia coli Nissle 1917 (EcN) on irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in a mouse model and in the human colonic cells lines Caco-2. Materials and methods: Male BALB/c mice received irinotecan intraperitoneal injection with or without EcN administration intragastrically. Body weight, diarrhea severity, intestinal permeability and histopathological analysis of ileum epithelia of mice from different groups were assessed. The expression and localization of tight junction proteins were examined using western blot and immunofluorescence. Gut microbiota structure and diversity were measured with 16 S rRNA sequencing. Caco-2 monolayers were incubated with EcN culture supernatant (EcN(sup)) or SN-38 and the monolayer barrier function was assessed by transepithelial electrical resistance (TER) and FITC-dextran 4000 Da (FD-4) flux. Key findings: Pretreatment with EcN significantly attenuated irinotecan-induced weight loss and diarrhea in mice. In addition, EcN inhibited the increased intestinal permeability and decreased Claudin-1 expression in irinotecan-treated mice. Furthermore, irinotecan treatment decreased the diversity of gut microbiota and increased the relative abundance of Proteobacteria compared to control group. EcN administration ameliorated the gut microbiota dysbiosis. In Caco-2 monolayers, EcN(sup) ameliorated the decreased TER and increased FD-4 flux elicited by SN-38. Moreover, EcN(sup) attenuated SN-38-induced altered localization and distribution of Claudin-1 in Caco-2 monolayers. Significance: Our results indicated that the administration of EcN protected against irinotecan-induced intestinal injury by regulating intestinal barrier function and gut microbiota.

Advances in functional studies of probiotic Escherichia coli Nissle1917

Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications.

Screening of Novel Probiotics with Intestinal Peristalsis-Promoting Potential Based on in Vitro and in Vivo Investigations

Expectations for employing Escherichia coli Nissle 1917 in food science and nutrition

Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways

Improving the growth and intestinal colonization of Escherichia coli Nissle 1917 by strengthening its oligopeptides importation ability

Engineered probiotic E.coli Nissle 1917 for release PTEN to improve the tumor microenvironment and suppress tumor growth

Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies

Comprehensive Analysis of the Physiological Characterization of Escherichia coli Nissle 1917

The Administration of Escherichia Coli Nissle 1917 Ameliorates Irinotecan-Induced Intestinal Barrier Dysfunction and Gut Microbial Dysbiosis in Mice.

Microfluidics-Derived Microparticles with Prebiotics and Probiotics for Enhanced in Situ Colonization and Immunoregulation of Colitis.

Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917

Escherichia Coli Nissle 1917 Protects Intestinal Barrier Function by Inhibiting NF-κB-Mediated Activation of the MLCK-P-MLC Signaling Pathway.

Physiologically Inspired Mucin Coated Escherichia coli Nissle 1917 Enhances Biotherapy by Regulating the Pathological Microenvironment to Improve Intestinal Colonization

Encapsulation of Escherichia coli strain Nissle 1917 in a chitosan-alginate matrix by combining layer-by-layer assembly with CaCl2 cross-linking for an effective treatment of inflammatory bowel diseases

Non-pathogenic Trojan horse Nissle1917 triggers mitophagy through PINK1/Parkin pathway to discourage colon cancer

Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery

<i>Escherichia</i><i>coli</i> Nissle 1917 as a Novel Microrobot for Tumor-Targeted Imaging and Therapy

Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy

Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice

Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish